Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01948063 · ClinicalTrials.gov registry record · Phase 2
Ubiquinol (Reduced COQ10) for Patients With Sepsis
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01948063 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 38 participants.
The verdict
NCT01948063, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Ubiquinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01948063
The ClinicalTrials.gov registry entry for NCT01948063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01948063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01948063 about?
NCT01948063 is a clinical study titled "Ubiquinol (Reduced COQ10) for Patients With Sepsis". This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.
What is the current status of trial NCT01948063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2012-10. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01948063?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Ubiquinol (DRUG).
Who is sponsoring clinical trial NCT01948063?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.